JP2006523720A - 胸腺再生前の移植片に対する寛容 - Google Patents

胸腺再生前の移植片に対する寛容 Download PDF

Info

Publication number
JP2006523720A
JP2006523720A JP2006513099A JP2006513099A JP2006523720A JP 2006523720 A JP2006523720 A JP 2006523720A JP 2006513099 A JP2006513099 A JP 2006513099A JP 2006513099 A JP2006513099 A JP 2006513099A JP 2006523720 A JP2006523720 A JP 2006523720A
Authority
JP
Japan
Prior art keywords
cells
patient
cell
donor
thymus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006513099A
Other languages
English (en)
Japanese (ja)
Inventor
ガブリエル・リアンヌ・ゴールドバーグ
ジェーン・スザンヌ・サザーランド
アン・パトリシア・チッゲイ
リチャード・ボイド
Original Assignee
ノーウッド・イミュノロジー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/419,039 external-priority patent/US20040037816A1/en
Application filed by ノーウッド・イミュノロジー・リミテッド filed Critical ノーウッド・イミュノロジー・リミテッド
Publication of JP2006523720A publication Critical patent/JP2006523720A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006513099A 2003-04-18 2004-04-19 胸腺再生前の移植片に対する寛容 Withdrawn JP2006523720A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/419,039 US20040037816A1 (en) 1999-04-15 2003-04-18 Graft acceptance through manipulation of thymic regeneration
US52700103P 2003-12-05 2003-12-05
US10/749,119 US20040258672A1 (en) 1999-04-15 2003-12-30 Graft acceptance through manipulation of thymic regeneration
PCT/US2004/011919 WO2004094988A2 (en) 2003-04-18 2004-04-19 Tolerance to graft prior to thymic regeneration

Publications (1)

Publication Number Publication Date
JP2006523720A true JP2006523720A (ja) 2006-10-19

Family

ID=33314188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006513099A Withdrawn JP2006523720A (ja) 2003-04-18 2004-04-19 胸腺再生前の移植片に対する寛容

Country Status (7)

Country Link
US (1) US20040258672A1 (ko)
EP (2) EP1620125A4 (ko)
JP (1) JP2006523720A (ko)
KR (1) KR20060025134A (ko)
AU (1) AU2004233019A1 (ko)
CA (1) CA2528503A1 (ko)
WO (2) WO2004094988A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
WO2004094599A2 (en) * 2003-04-18 2004-11-04 Norwood Immunology, Ltd. Disease prevention and vaccination following thymic reactivation
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
CA2619503A1 (en) * 2005-06-28 2007-01-04 Robert F. Casper Aromatase inhibitors for emergency contraception
CN103292469A (zh) * 2011-06-28 2013-09-11 李君� 一种温水锅炉、蒸汽换热锅炉的节能减排装置
WO2022011284A1 (en) * 2020-07-10 2022-01-13 Ohio State Innovation Foundation Epidermal growth factor-like 7 peptide and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US43245A (en) * 1864-06-21 Maurice vebgnes
US434571A (en) * 1890-08-19 Filter
FR2238700B1 (ko) * 1973-07-24 1977-10-14 Takeda Chemical Industries Ltd
JPS5726506B2 (ko) * 1974-03-08 1982-06-04
CS180644B2 (en) * 1973-09-29 1978-01-31 Takeda Chemical Industries Ltd Process for preparing nonapeptides
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3992365A (en) * 1973-11-01 1976-11-16 Burroughs Wellcome Co. Agonist analogues of luteinizing hormone releasing hormone
JPS50142563A (ko) * 1974-04-26 1975-11-17
NL7505590A (nl) * 1974-05-18 1975-11-20 Hoechst Ag Werkwijze voor het bereiden van peptiden met lh-rh/fsh-rh-werking.
AU497512B2 (en) * 1975-04-15 1978-12-14 Ici Australia Limited Nona and deca-peptides
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4049805A (en) * 1975-09-30 1977-09-20 Akzona Incorporated Steroidal erythropoietic agents and therapeutic compositions and methods
DE2617646C2 (de) * 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4089946A (en) * 1976-06-07 1978-05-16 American Home Products Corporation Claudogenic-interceptive nonapeptides
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
DE2905502C2 (de) * 1979-02-14 1982-07-15 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von LH-RH bzw. LH-RH-Analoga und Pyroglutamyl-N↑i↑m↑-dinitrophenyl-histidin
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US5003011A (en) * 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4642332A (en) * 1985-04-26 1987-02-10 The Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-Pal6 -LHRH
US4656247A (en) * 1985-04-26 1987-04-07 Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-QA1 6-LHRH
US4775361A (en) * 1986-04-10 1988-10-04 The General Hospital Corporation Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport
US4992421A (en) * 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5258492A (en) * 1988-10-21 1993-11-02 The Administrators Of The Tulane Educational Fund LHRH analogues with cytotoxic moieties at the sixth position
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5144019A (en) * 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5434136A (en) * 1990-12-14 1995-07-18 Mathias; John R. Treatment of motility disorders with a GNRH analog
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
CA2121370C (en) * 1991-11-22 2003-03-18 David H. Sachs Specific tolerance in transplantation
ES2172514T3 (es) * 1992-01-08 2002-10-01 Gen Hospital Corp Tolerancia inducida a los xenoinjertos.
US5658564A (en) * 1992-02-19 1997-08-19 The General Hospital Corporation Xenograft thymus
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5643252A (en) * 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5614502A (en) * 1993-01-15 1997-03-25 The General Hospital Corporation High-pressure impulse transient drug delivery for the treatment of proliferative diseases
US5658892A (en) * 1993-01-15 1997-08-19 The General Hospital Corporation Compound delivery using high-pressure impulse transients
WO1994026877A1 (en) * 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US5650306A (en) * 1993-06-07 1997-07-22 University Of Michigan Recombinant nucleic acids for inhibiting HIV gene expression
WO1995005843A1 (en) * 1993-08-25 1995-03-02 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
US20010009663A1 (en) * 1993-09-13 2001-07-26 Suzanne T. Ildstad Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6056738A (en) * 1997-01-31 2000-05-02 Transmedica International, Inc. Interstitial fluid monitoring
JPH07166906A (ja) * 1993-12-14 1995-06-27 Nissan Motor Co Ltd 燃料カットと点火時期変更による加速スリップ制御装置
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
GB9409985D0 (en) * 1994-05-18 1994-07-06 Medical Res Council Vaccine against mycobacterial infections
US5814617A (en) * 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
CA2227241C (en) * 1995-07-21 2004-12-21 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
AU723003C (en) * 1995-08-04 2004-01-29 General Hospital Corporation, The Transgenic swine and swine cells having human HLA genes
US5824322A (en) * 1995-08-21 1998-10-20 Cytrx Corporation Compositions and methods for growth promotion
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5658822A (en) * 1996-03-29 1997-08-19 Vanguard International Semiconductor Corporation Locos method with double polysilicon/silicon nitride spacer
US6776986B1 (en) * 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5741706A (en) * 1996-06-13 1998-04-21 Immusol, Incorporated Anti-HIV ribozymes
WO1998020932A2 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
EP0957980A4 (en) * 1996-11-27 2000-03-29 Gen Hospital Corp DELIVERY OF COMPOUNDS BY MEANS OF IMPULSE TRANSIENT PHENOMENES
US5985892A (en) * 1998-04-02 1999-11-16 Merck & Co., Ltd. Antagonists of gonadotropin releasing hormone
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU2980900A (en) * 1999-02-04 2000-08-25 General Hospital Corporation, The Methods for human allografting
AUPP977899A0 (en) * 1999-04-15 1999-05-13 Monash University Improvement of t cell mediated immunity
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20020136704A1 (en) * 1999-04-15 2002-09-26 Richard Boyd Diagnostic indicator of thymic function
WO2002031195A1 (en) * 2000-10-11 2002-04-18 Duke University Assay for detecting and quantitating mouse t cell receptor excision circles
EP1345574A4 (en) * 2000-10-13 2006-05-31 Univ Monash IMPROVING ACCEPTANCE OF TRANSPLANTS BY CONTROLLING THYME REGENERATION
AP2003002800A0 (en) * 2000-10-13 2003-06-30 Richard Boyd Hematopoietic stem cell gene therapy
US6759551B1 (en) * 2000-11-03 2004-07-06 Bayer Cropscience S.A. Chiral (s- or r-methylphenylglycine) amino acid crystal and method for preparing same
US20050043245A1 (en) * 2003-08-11 2005-02-24 Siler -Khodr Theresa M. Non-mammalian GnRH analogs and uses thereof in the immune system

Also Published As

Publication number Publication date
WO2004094988A2 (en) 2004-11-04
WO2004094649A2 (en) 2004-11-04
EP1619952A2 (en) 2006-02-01
KR20060025134A (ko) 2006-03-20
EP1620125A2 (en) 2006-02-01
CA2528503A1 (en) 2004-11-04
AU2004233019A1 (en) 2004-11-04
US20040258672A1 (en) 2004-12-23
EP1619952A4 (en) 2009-07-22
WO2004094988A3 (en) 2005-12-01
EP1620125A4 (en) 2009-11-04
WO2004094649A3 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
AU734665B2 (en) Mixed chimerism and tolerance
Rossi et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease
Goldberg et al. Sex steroid ablation enhances immune reconstitution following cytotoxic antineoplastic therapy in young mice
JP2002502824A (ja) 同種移植における補刺激遮断および混合キメラ現象
Goldberg et al. Clinical strategies to enhance T cell reconstitution
US20080279812A1 (en) Disease Prevention and Vaccination Prior to Thymic Reactivation
US20050020524A1 (en) Hematopoietic stem cell gene therapy
US20040132179A1 (en) Treatment of t cell disorders
JP2007518699A (ja) 胸腺再生前の病気の予防およびワクチン接種
JP2006523720A (ja) 胸腺再生前の移植片に対する寛容
US20040259803A1 (en) Disease prevention by reactivation of the thymus
US20070274946A1 (en) Tolerance to Graft Prior to Thymic Reactivation
US20050042679A1 (en) Diagnostic indicator of thymic function
US20040265285A1 (en) Normalization of defective T cell responsiveness through manipulation of thymic regeneration
ZA200509363B (en) Tolerance to graft prior to thymic regeneration
GOLDBERG et al. Patent 2528521 Summary
ZA200509362B (en) Disease prevention and vaccination prior to thymic reactivations
AU2001295270B2 (en) Treatment of T cell disorders
US20060088512A1 (en) Treatment of T cell disorders
EP1048298B1 (en) Mixed chimerism and tolerance
Gabriel Apoptosis modulation in lymphocytes as novel concept for tolerance induction and bone marrow transplantation to alleviate a renal tubulopathy
EP1310260A1 (en) Mixed chimerism and tolerance

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070403

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090529